BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev 2014;:CD010590. [PMID: 25486075 DOI: 10.1002/14651858.CD010590.pub2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Ingrasciotta Y, Giorgianni F, Marcianò I, Bolcato J, Pirolo R, Chinellato A, Ientile V, Santoro D, Genazzani AA, Alibrandi A, Fontana A, Caputi AP, Trifirò G. Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study. PLoS One 2016;11:e0155805. [PMID: 27187174 DOI: 10.1371/journal.pone.0155805] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
2 Vu K, Zhou J, Everhart A, Desai N, Herrin J, Jena AB, Ross JS, Shah ND, Karaca-Mandic P. Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial. BMC Nephrol 2021;22:284. [PMID: 34419007 DOI: 10.1186/s12882-021-02491-y] [Reference Citation Analysis]
3 Whittaker CF, Miklich MA, Patel RS, Fink JC. Medication Safety Principles and Practice in CKD. Clin J Am Soc Nephrol 2018;13:1738-46. [PMID: 29915131 DOI: 10.2215/CJN.00580118] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
4 Mesgarpour B, Heidinger BH, Roth D, Schmitz S, Walsh CD, Herkner H. Harms of off-label erythropoiesis-stimulating agents for critically ill people. Cochrane Database Syst Rev 2017;8:CD010969. [PMID: 28841235 DOI: 10.1002/14651858.CD010969.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
5 Winkelmayer WC, Chang TI, Mitani AA, Wilhelm-Leen ER, Ding V, Chertow GM, Brookhart MA, Goldstein BA. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study. Am J Kidney Dis 2015;66:106-13. [PMID: 25943715 DOI: 10.1053/j.ajkd.2015.02.339] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
6 Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev 2014;:CD010590. [PMID: 25486075 DOI: 10.1002/14651858.CD010590.pub2] [Reference Citation Analysis]
7 Macdougall IC, Akizawa T, Berns JS, Bernhardt T, Krueger T. Effects of Molidustat in the Treatment of Anemia in CKD. Clin J Am Soc Nephrol 2019;14:28-39. [PMID: 30559105 DOI: 10.2215/CJN.02510218] [Cited by in Crossref: 38] [Cited by in F6Publishing: 24] [Article Influence: 9.5] [Reference Citation Analysis]
8 Robles NR. The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease. Clin Drug Investig 2016;36:421-31. [PMID: 26894799 DOI: 10.1007/s40261-016-0378-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
9 Cohen AD, Vender R, Naldi L, Kalb RE, Torres T, Rajagopalan M, van der Walt J, Puig L, Young HS. Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis Council. JAAD Int 2020;1:224-30. [PMID: 34409344 DOI: 10.1016/j.jdin.2020.09.006] [Reference Citation Analysis]
10 Haase VH, Chertow GM, Block GA, Pergola PE, deGoma EM, Khawaja Z, Sharma A, Maroni BJ, McCullough PA. Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents. Nephrol Dial Transplant 2019;34:90-9. [PMID: 29672740 DOI: 10.1093/ndt/gfy055] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 14.7] [Reference Citation Analysis]
11 Pál S, Faust Z, Réger B, Miseta A, Varjú-solymár M, Nemes-nagy E, Tilinca MC, Alizadeh H. Evaluation of iron replacement therapy efficiency using a complex panel of biomarkers. Revista Romana de Medicina de Laborator 2022;30:97-105. [DOI: 10.2478/rrlm-2022-0005] [Reference Citation Analysis]
12 Hougen I, Collister D, Bourrier M, Ferguson T, Hochheim L, Komenda P, Rigatto C, Tangri N. Safety of Intravenous Iron in Dialysis: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol 2018;13:457-67. [PMID: 29463597 DOI: 10.2215/CJN.05390517] [Cited by in Crossref: 38] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
13 Chanu P, Schaefer F, Warady BA, Schmitt CP, Reigner B, Schnetzler G, Meyer Reigner S, Eisner M, Weichert A, Frey N. Model-based approach for methoxy polyethylene glycol-epoetin beta drug development in paediatric patients with anaemia of chronic kidney disease. Br J Clin Pharmacol 2020;86:801-11. [PMID: 31770451 DOI: 10.1111/bcp.14186] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Portolés J, Martín L, Broseta JJ, Cases A. Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. Front Med (Lausanne) 2021;8:642296. [PMID: 33842503 DOI: 10.3389/fmed.2021.642296] [Reference Citation Analysis]
15 Spineli LM, Kalyvas C, Papadimitropoulou K. How robust are findings of pairwise and network meta-analysis in the presence of missing participant outcome data? BMC Med 2021;19:323. [PMID: 34930276 DOI: 10.1186/s12916-021-02195-y] [Reference Citation Analysis]
16 Chen J, Wang F, Huang S, Liu X, Li Z, Qi A, Liu X, Yi T, Li S. Jian-Pi-Yi-Shen Decoction Relieves Renal Anemia in 5/6 Nephrectomized Rats: Production of Erythropoietin via Hypoxia Inducible Factor Signaling. Evid Based Complement Alternat Med 2019;2019:2807926. [PMID: 30941190 DOI: 10.1155/2019/2807926] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
17 Saglimbene VM, Palmer SC, Ruospo M, Natale P, Craig JC, Strippoli GF. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease. Cochrane Database Syst Rev 2017;8:CD009904. [PMID: 28782299 DOI: 10.1002/14651858.CD009904.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
18 Weaver DJ Jr, Somers MJG, Martz K, Mitsnefes MM. Clinical outcomes and survival in pediatric patients initiating chronic dialysis: a report of the NAPRTCS registry. Pediatr Nephrol 2017;32:2319-30. [PMID: 28762101 DOI: 10.1007/s00467-017-3759-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 25] [Article Influence: 11.0] [Reference Citation Analysis]
19 Hahn D, Esezobor CI, Elserafy N, Webster AC, Hodson EM. Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients. Cochrane Database Syst Rev 2017;1:CD011690. [PMID: 28066881 DOI: 10.1002/14651858.CD011690.pub2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
20 Tanaka T, Nangaku M, Imai E, Tsubakihara Y, Kamai M, Wada M, Asada S, Akizawa T. Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan. Clin Exp Nephrol 2019;23:231-43. [PMID: 30182223 DOI: 10.1007/s10157-018-1632-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
21 Sakaguchi Y, Hamano T, Wada A, Masakane I. Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis. J Am Soc Nephrol 2019;30:1037-48. [PMID: 31015255 DOI: 10.1681/ASN.2018101007] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 12.7] [Reference Citation Analysis]
22 Naber T, Purohit S. Chronic Kidney Disease: Role of Diet for a Reduction in the Severity of the Disease. Nutrients 2021;13:3277. [PMID: 34579153 DOI: 10.3390/nu13093277] [Reference Citation Analysis]
23 Del Vecchio L, Minutolo R. ESA, Iron Therapy and New Drugs: Are There New Perspectives in the Treatment of Anaemia? J Clin Med 2021;10:839. [PMID: 33670704 DOI: 10.3390/jcm10040839] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Wilhelm-Leen ER, Winkelmayer WC. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis. Am J Kidney Dis 2015;66:69-74. [PMID: 25636816 DOI: 10.1053/j.ajkd.2014.12.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.9] [Reference Citation Analysis]
25 Santos EJF, Dias RSC, Lima JFB, Salgado Filho N, Miranda Dos Santos A. Erythropoietin Resistance in Patients with Chronic Kidney Disease: Current Perspectives. Int J Nephrol Renovasc Dis 2020;13:231-7. [PMID: 33116754 DOI: 10.2147/IJNRD.S239151] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Gowanlock Z, Sriram S, Martin A, Xenocostas A, Lazo-Langner A. Erythropoiesis-stimulating agents in elderly patients with anemia: response and cardiovascular outcomes. Blood Adv 2017;1:1538-45. [PMID: 29296795 DOI: 10.1182/bloodadvances.2017007559] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
27 Wu MY, Chen YC, Lin CH, Wu YC, Tu YK, Tarng DC. Safety and efficacy of ferric citrate in phosphate reduction and iron supplementation in patients with chronic kidney disease. Oncotarget 2017;8:107283-94. [PMID: 29291028 DOI: 10.18632/oncotarget.21990] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
28 Hou W, Ding M, Li X, Zhou X, Zhu Q, Varela-Ramirez A, Yi C. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials. J Cancer Res Clin Oncol 2021;147:2407-20. [PMID: 33725154 DOI: 10.1007/s00432-021-03521-w] [Reference Citation Analysis]
29 Trotta F, Belleudi V, Fusco D, Amato L, Mecozzi A, Mayer F, Sansone M, Davoli M, Addis A. Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy. BMJ Open 2017;7:e011637. [PMID: 28283484 DOI: 10.1136/bmjopen-2016-011637] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
30 Dardiotis E, Aloizou AM, Markoula S, Siokas V, Tsarouhas K, Tzanakakis G, Libra M, Kyritsis AP, Brotis AG, Aschner M, Gozes I, Bogdanos DP, Spandidos DA, Mitsias PD, Tsatsakis A. Cancer-associated stroke: Pathophysiology, detection and management (Review). Int J Oncol 2019;54:779-96. [PMID: 30628661 DOI: 10.3892/ijo.2019.4669] [Cited by in Crossref: 14] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
31 Minutolo R, Bolasco P, Chiodini P, Sposini S, Borzumati M, Abaterusso C, Mele AA, Santoro D, Canale V, Santoboni A, Filiberti O, Fiorini F, Mura C, Imperiali P, Borrelli S, Russo L, De Nicola L, Russo D. Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients. Clin Drug Investig 2017;37:965-73. [PMID: 28779268 DOI: 10.1007/s40261-017-0562-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
32 Drüeke TB, Massy ZA. Erythropoiesis-Stimulating Agents and Mortality. J Am Soc Nephrol 2019;30:907-8. [PMID: 31015256 DOI: 10.1681/ASN.2019030266] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
33 Zhang C, Wang J, Xie X, Sun D. Low serum vitamin D concentration is correlated with anemia, microinflammation, and oxidative stress in patients with peritoneal dialysis. J Transl Med 2021;19:411. [PMID: 34579742 DOI: 10.1186/s12967-021-03077-w] [Reference Citation Analysis]
34 Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev 2014;:CD010590. [PMID: 25486075 DOI: 10.1002/14651858.CD010590.pub2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
35 Zhang BL, Yang XH, Jin HM, Zhan XL. Identification of differentially expressed genes in diabetic kidney disease by RNA-Seq analysis of venous blood platelets. FEBS Open Bio 2021. [PMID: 34029013 DOI: 10.1002/2211-5463.13199] [Reference Citation Analysis]
36 Belleudi V, Trotta F, Addis A, Ingrasciotta Y, Ientile V, Tari M, Gini R, Pastorello M, Scondotto S, Cananzi P, Traversa G, Davoli M, Trifirò G; Italian Biosimilar Network (ItaBioNet). Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study. Drug Saf 2019;42:1437-47. [PMID: 31228010 DOI: 10.1007/s40264-019-00845-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
37 Locatelli F, Choukroun G, Truman M, Wiggenhauser A, Fliser D. Once-Monthly Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Hemodialysis-Dependent Chronic Kidney Disease: Pooled Data from Phase III Trials. Adv Ther 2016;33:610-25. [PMID: 26965694 DOI: 10.1007/s12325-016-0309-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
38 Motola D, Vaccheri A, Roncadori A, Donati M, Bonaldo G, Covezzoli A, Polidori P, Bianchi S. Comparative risk/benefit profile of biosimilar and originator erythropoiesis-stimulating agents (ESAs): data from an Italian observational study in nephrology. Eur J Clin Pharmacol 2018;74:805-10. [PMID: 29429032 DOI: 10.1007/s00228-018-2428-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
39 Chen MC, Ho YF, Lin CC, Wu CC. Development and testing of the hemodialysis symptom distress scale (HSD-22) to identify the symptom cluster by using exploratory factor analysis. BMC Nephrol 2021;22:128. [PMID: 33845793 DOI: 10.1186/s12882-021-02337-7] [Reference Citation Analysis]
40 Prochaska MT, Newcomb R, Block G, Park B, Meltzer DO. Association Between Anemia and Fatigue in Hospitalized Patients: Does the Measure of Anemia Matter? J Hosp Med 2017;12:898-904. [PMID: 29091977 DOI: 10.12788/jhm.2832] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]